Skip to main content

Diazepam

ADVERTISEMENT
Identification
Molecular formula
C16H13ClFN3O
CAS number
439-14-5
IUPAC name
7-chloro-5-(2-fluorophenyl)-1-[3-(4-methylpiperazin-1-yl)propyl]-3H-1,4-benzodiazepin-2-one
State
State

Diazepam is a solid at room temperature. It is commonly available in crystalline powder form and is typically used in tablet or solution formulations for oral or intravenous administration in clinical settings.

Melting point (Celsius)
131.50
Melting point (Kelvin)
404.65
Boiling point (Celsius)
383.90
Boiling point (Kelvin)
657.05
General information
Molecular weight
284.72g/mol
Molar mass
284.7150g/mol
Density
1.3000g/cm3
Appearence

Diazepam is typically a white to yellow crystalline powder. It is often odorless and has a slightly bitter taste. The compound may also be available in tablet form for medical use, appearing as small, round, coloretablets. Commercially, it is often supplied as tablets or solutions for oral or intravenous use.

Comment on solubility

Solubility of 7-chloro-5-(2-fluorophenyl)-1-[3-(4-methylpiperazin-1-yl)propyl]-3H-1,4-benzodiazepin-2-one

The solubility of 7-chloro-5-(2-fluorophenyl)-1-[3-(4-methylpiperazin-1-yl)propyl]-3H-1,4-benzodiazepin-2-one exhibits certain characteristics that are essential for its application in pharmaceutical contexts. Understanding its solubility can provide insights into its bioavailability, pharmacokinetics, and formulation strategies.

Key considerations regarding solubility include:

  • Solvent Dependence: This compound may show varying solubility in different solvents, often demonstrating higher solubility in organic solvents compared to aqueous environments.
  • Temperature Effects: Generally, an increase in temperature may enhance solubility due to the greater kinetic energy, leading to more effective solvation.
  • pH Sensitivity: The solubility can be affected by the pH of the solution, especially for compounds with ionizable functional groups, potentially changing their state from neutral to charged.

In practice, the solubility profile can guide the appropriate delivery methods and dosage forms of the drug. As a rule of thumb, "the higher the solubility, the easier it is to formulate." Furthermore, achieving optimal solubility can enhance therapeutic efficacy while minimizing potential side effects.

Overall, exploring and optimizing the solubility of this compound could lead to better patient outcomes and innovations in drug delivery systems.

Interesting facts

Interesting Facts about 7-Chloro-5-(2-fluorophenyl)-1-[3-(4-methylpiperazin-1-yl)propyl]-3H-1,4-benzodiazepin-2-one

This compound is a member of the benzodiazepine family, which is well-known for its use in pharmaceuticals. Benzodiazepines have a variety of effects, including anxiolytic, sedative, muscle relaxant, and anticonvulsant properties. Here are some interesting insights:

  • Benzodiazepine Class: The compound is derived from the benzodiazepine core structure, featuring a fused benzene and diazepine ring. This core is crucial for its biological activity.
  • Chemical Modifications: The specific substitutions at various positions of the ring, like the chloro and fluorophenyl groups, play an essential role in determining the pharmacological properties and potency of the compound.
  • Pharmacology: It is expected that this compound may exhibit enhanced activity due to the 4-methylpiperazin-1-yl group, which can increase lipophilicity and aids in crossing the blood-brain barrier effectively.
  • Potential Applications: Given its structural features, this compound holds promise in treating anxiety, sleep disorders, and other central nervous system conditions.
  • Research Interests: Ongoing research may focus on improving its efficacy, safety, and reducing side effects, as with many benzos that can be habit-forming or lead to tolerance over time.

As always, advancements in medicinal chemistry and drug design are essential for optimizing the therapeutic applications of such compounds. The focus remains on tailoring these benzodiazepine derivatives to enhance clinical outcomes while mitigating adverse effects.